As a leading CGM maker, DexCom is likely to play a significant role in diabetes care for years, possibly decades. Given all ...

DexCom faces significant headwinds, including slower customer growth and increased competition. Learn more on DXCM here.

These once-sizable artificial intelligence (AI) holdings for Google parent Alphabet have been paired down big-time over the ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

The announcement comes just after Dexcom, another diabetes company, released its own consumer-friendly sensor. Here's what to ...

Check the time stamp on this data. Updated AI-Generated Signals for Dexcom Inc. (DXCM) available here: DXCM.

New over-the-counter sensors, an Abbott-Medtronic partnership and Roche’s first CGM are among diabetes technology’s top stories so far in 2024. Check out MedTech Dive’s roundup of the latest news.

During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start. After taking a close look at the latest data on ...

The race between Donald Trump and Kamala Harris is close, and market strategists are studying which stocks will do best. Here ...

According to a recent FCC filing, the Oura Ring 4 is likely to launch any day now. In the meantime, however, the health ...

GeneDx is helping patients navigate through the "diagnostic odyssey" with DNA sequencing. The biotech stock is on its own odyssey.

Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetesWith a single sensor, the ...